Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17947401 | 0.90 | P4HB (0.51) | LPLLIPG | |
| SCHEMBL15481277 | 0.90 | P4HB (0.51) | LPLLIPG | |
| SCHEMBL12566977 | 0.83 | MAOB (0.56) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20401792 | 0.83 | LMNA (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL15981215 | 0.83 | MAOB (0.56) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL5950108 | 0.82 | P4HB (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21383656 | 0.82 | ALDH1A1 (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL228212 | 0.81 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1572672 | 0.81 | CYP19A1 (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21383659 | 0.81 | F2 (0.40) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406055-A | Compound DNNP, preparation method thereof and application thereof in detection of hydrogen sulfide | 江苏科技大学 | 2024-07-30 | — | — | CN | claimed |
| CN-109851550-A | 7- aminocarbazole sulfamide derivative and its preparation method and application | 中国医学科学院医药生物技术研究所 | 2019-06-07 | — | — | CN | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250152719-A1 | FUSED IMIDE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4536639-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | Oregon Health & Science University (US) | 2025-04-16 | — | — | EP | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-1127060-B8 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
| US-20040133028-A1 | Hydroboronation process | COMMONWEALTH SCIENTIFIC | 2004-07-08 | — | — | US | disclosed |
| EP-1127060-B1 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2004-04-07 | — | — | EP | disclosed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | disclosed |
| EP-1127060-A4 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1127060-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | LPL 3479/4885LIPG 3796/4885CA1 2799/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | LPL 293/4885LIPG 204/4885CA1 4658/4885 |
| US-20040133028-A1 | Hydroboronation process | ALKBH3, HPD, HVCN1 | LPL 4659/4885LIPG 4522/4885CA1 2357/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | LPL 3414/4885LIPG 3588/4885CA1 4765/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885CA1 1719/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885CA1 1719/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | LPL 3414/4885LIPG 3588/4885CA1 4765/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | LPL 1131/4885LIPG 1319/4885CA1 701/4885 |
| US-20250152719-A1 | FUSED IMIDE DERIVATIVE | WEE1, WEE2, CYP4F11 | LPL 4103/4885LIPG 3361/4885CA1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.